Travel Daily Media

TDM AWARDS - NOMINATE NOW!

Indians with Covaxin shots might have to delay international travel plans

Travellers from India who have been fully vaccinated by both doses of Covaxin might not be allowed to travel internationally as the vaccine produced by Bharat Biotech has not been included in World Health Organization’s (WHO) Emergency Use Listing (EUL) so far.

Several nations in Europe are reopening in a bid to boost their travel and tourism industries and are likely to make regulations for entry of travellers based on recommendations of their respective health departments or are likely to allow people vaccinated with the shots manufactured by companies which are on WHO’s EUL list.

India’s other vaccine – Covishield – manufactured by Pune-based Serum Institute of India is on WHO’s EUL. WHO listed the Pfizer/BioNTech vaccine for emergency use on December 31 last year; two AstraZeneca/Oxford Covid-19 vaccines on February 15, produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India; and the Covid-19 vaccine Ad26.COV2.S developed by Janssen (Johnson & Johnson) on March 12. The UN body has also granted approval to Moderna’s Covid-19 vaccine and included China’s Sinopharm COVID-19 vaccine in its EUL.

The Centre expanded its massive vaccination drive for people in the age group of 18 to 44 years on 1 May. Now, on-site registration for 18 and above at govt vaccination centres.

Covaxin, according to WHO’s Guideline Document on “Status of Covid-19 Vaccines within WHO EUL/PQ evaluation process”, will be reviewed during a meeting which will be held between the months of May and June 2021. The document also showed that the Hyderabad-based pharmaceutical company has submitted its expression of interest on 19 April.

(Source: Hindustan Times)

Join The Community

Join The Community

TDM

x Studio

Connect with your clients by working with our in-house brand studio, using our expertise and media reach to help you create and craft your message in video and podcast, native content and whitepapers, webinars and event formats.

Indians with Covaxin shots might have to delay international travel plans

Travellers from India who have been fully vaccinated by both doses of Covaxin might not be allowed to travel internationally as the vaccine produced by Bharat Biotech has not been included in World Health Organization’s (WHO) Emergency Use Listing (EUL) so far.

Several nations in Europe are reopening in a bid to boost their travel and tourism industries and are likely to make regulations for entry of travellers based on recommendations of their respective health departments or are likely to allow people vaccinated with the shots manufactured by companies which are on WHO’s EUL list.

India’s other vaccine – Covishield – manufactured by Pune-based Serum Institute of India is on WHO’s EUL. WHO listed the Pfizer/BioNTech vaccine for emergency use on December 31 last year; two AstraZeneca/Oxford Covid-19 vaccines on February 15, produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India; and the Covid-19 vaccine Ad26.COV2.S developed by Janssen (Johnson & Johnson) on March 12. The UN body has also granted approval to Moderna’s Covid-19 vaccine and included China’s Sinopharm COVID-19 vaccine in its EUL.

The Centre expanded its massive vaccination drive for people in the age group of 18 to 44 years on 1 May. Now, on-site registration for 18 and above at govt vaccination centres.

Covaxin, according to WHO’s Guideline Document on “Status of Covid-19 Vaccines within WHO EUL/PQ evaluation process”, will be reviewed during a meeting which will be held between the months of May and June 2021. The document also showed that the Hyderabad-based pharmaceutical company has submitted its expression of interest on 19 April.

(Source: Hindustan Times)

Join The Community

Stay Connected

Facebook

101K

Twitter

3.9K

Instagram

1.7K

LinkedIn

19.9K

YouTube

0.2K

TDM

x Studio

Connect with your clients by working with our in-house brand studio, using our expertise and media reach to help you create and craft your message in video and podcast, native content and whitepapers, webinars and event formats.

Scroll to Top